3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
19
Paclitaxel
17
Cisplatin
9
Cyclophosphamide
8
Gemcitabine
7
Bevacizumab
6
Topotecan
5
pembrolizumab
4
olaparib
4
liposomal doxorubicin
4
durvalumab
4
Letrozole
4
Interleukin-2
4
Drug Therapy
4
Doxorubicin
4
Albumin-Bound Paclitaxel
4
rucaparib
3
fludarabine
3
chiauranib
3
cemiplimab
3
camrelizumab
3
Therapeutics
3
Itraconazole
3
Injections
3
Hyperthermic Intraperitoneal Chemotherapy
3
Everolimus
3
pazopanib
2
iniparib
2
eprenetapopt
2
avelumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tinostamustine
×
Gynecologic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts